1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Vivimed Labs Limited

Vivimed Labs Limited

6.21
INR
-0.12
(-1.90%)
-21.27EPS
437.79MMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
166.73
170.27
830.32
151.19
143.13
153.28
119.1
103.87
28.53
22.57
17.98
14.01
8.44
8.44
Basic EPS, GAAP
8.19
8.89
51.64
26.41
9.44
6.95
-13.16
-9.38
-8.16
-39.62
-5.48
-3.85
-21.28
-21.27
Free Cash Flow per Basic Share
-34.17
1.99
58.89
7.15
2.6
51.15
9.6
68.4
3.32
4.26
-2.89
-0.14
0.93
- -
Dividend per Share
1.98
- -
7.2
0.49
0.48
38.45
0.16
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
61.27
61.13
57.25
90.62
148.61
114.37
100.66
52.05
43.94
4.75
-0.66
-4.24
-25.39
-25.39
Tangible Book Value per Share
48.91
46.67
45
62.66
113.39
77.66
58.82
33.53
24.96
-14.26
-19.36
-22.73
-43.32
-43.32
Basic Weighted Avg Shares
81
81
16
81
83
83
83
83
83
83
83
83
83
83
Sales/Revenue/Turnover
13,508
13,795
13,454
12,249
11,812
12,649
9,875
8,615
2,366
1,871
1,491
1,163
700
700
Operating Margin (%)
10.89
11.02
13.49
30
13.21
10.05
-4.47
-2.54
-11.04
-109.94
-13.85
-28.62
-255.02
-255.03
Depreciation Expense
661
662
614
583
564
668
669
555
183
1,084
199
202
261
261
Net Income, GAAP
664
721
837
2,140
779
574
-1,091
-778
-676
-3,285
-454
-320
-1,765
-1,765
Effective Tax Rate (%)
23.56
7.08
16.27
25.31
11.22
13.14
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
4.92
5.22
6.22
17.47
6.6
4.54
-11.05
-9.03
-28.6
-175.59
-30.49
-27.49
-252.14
-252.14
Working Capital
2,265
1,911
2,238
2,770
4,917
3,417
2,190
1,876
1,339
-851
-677
-806
-2,801
-2,801
LT Debt
4,197
4,834
3,261
4,533
3,252
4,248
4,708
578
610
642
645
636
715
715
Total Equity
5,604
5,592
5,278
7,342
12,387
9,438
8,346
4,316
3,643
394
-55
-352
-2,106
-2,106
Return on Invested Capital (%)
5.39
4.92
9.85
16.46
6.94
5.39
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
9.13
9.94
9.93
16.05
6.6
5.4
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
14.1
14.53
17.45
35.72
7.95
5.29
-12.27
-12.29
-17
-162.76
- -
- -
- -
- -

Capital Structure

INR

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
3,207
- -
3,258
LT Borrowings
634
- -
715
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
83
83
83
Market Capitalization
- -
1,465
438

Working Capital

INR

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
3,406
- -
1,680
Cash, Cash Equivalents & STI
490
- -
77
Accounts Receivable, Net
893
- -
453
Inventories
527
- -
127
Total Current Liabilities
4,346
- -
4,481
Payables & Accruals
- -
- -
- -
ST Debt
3,207
- -
3,258
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
84.82%
164.81%
498.69%
Free Cash Flow
119.97%
-220.09%
-770.41%
Net Income, GAAP
45.58%
141.78%
452.15%
Sales/Revenue/Turnover
-21.57%
-35.12%
-39.8%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
354
336
415
386
1,491
2025
294
248
365
256
1,163
2026
214
206
160
120
700

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-1.88
-2.45
-1.94
0.63
-5.48
2025
-1.84
-0.62
-0.72
-0.68
-3.85
2026
-0.66
-0.88
-2
-17.74
-21.28

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Santosh Varalwar
Full Time Employees
586
Sector
Health technology
Industry
Pharmaceuticals: major
Address
6-3-866/1/G 1, GMR Towers Hyderabad TS India 500016
IPO Date
Aug 13, 2005
Website
vivimedlabs.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Vivimed Labs Ltd, headquartered in Hyderabad, India and founded in 1988, manufactures and supplies specialty chemicals and pharmaceutical products to global markets in over 50 countries. The company produces active pharmaceutical ingredients including generic APIs and intermediates via its subsidiary Uquifa with facilities in Spain and Mexico; finished dosage formulations such as tablets, capsules, syrups, ointments and nasal sprays for areas including diabetes, tuberculosis, oncology, nutritional supplements, hygiene and infectious diseases; and specialty chemicals encompassing active ingredients for home and personal care like triclosan preservatives, sunscreens, anti-wrinkle agents, skin lighteners, anti-dandruff compounds, hair growth promoters, hair conditioners, anti-microbials and oral care products, alongside hair dyes under the Jarocol brand, photochromic dyes under Reversacol, imaging chemicals, nutraceuticals, natural actives, colors and dyes. It operates manufacturing plants in India including sites in Hyderabad, Haridwar, Kashipur and Bidar, R&D labs in India and the UK, and strategic business units Vivimed Labs USA Inc and Vivimed Labs Europe with a marketing office in China; the company provides contract development and manufacturing organization services in APIs and formulations targeting pharmaceutical firms, personal care brands and industrial clients primarily in the US, Europe, erstwhile USSR countries, Africa and Asia. Recent developments include the 2023 acquisition of a US FDA-approved solid oral dosage facility in Alathur, Tamil Nadu from Actavis Pharma Manufacturing for Rs 122 crore along with two Abbreviated New Drug Applications to bolster generics revenue; in October 2025, its debt obligations were assigned from State Bank of India to Rare Asset Reconstruction Ltd encompassing all security interests to support financial restructuring; and ongoing quarterly financial reporting shows net sales of Rs 25.61 crore for Q4 FY2025 with persistent losses amid sales declines, reflecting efforts to stabilize operations through asset optimization and compliance-focused expansions.